These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 32586908)

  • 1. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
    Schjesvold FH; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; van de Velde H; Bensfia S; Bringhen S
    Haematologica; 2021 Apr; 106(4):1182-1187. PubMed ID: 32586908
    [No Abstract]   [Full Text] [Related]  

  • 2. Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
    Schjesvold F; Bringhen S; G Richardson P; Perrot A; Leleu X; Moreau P; A Dimopoulos M; Hulin C; Tekle C; Foster MC; Poole EM; van de Velde H; Facon T
    Am J Hematol; 2021 Nov; 96(11):E423-E427. PubMed ID: 34383345
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Richardson PG; Facon T; Bensinger WI; Leleu X; Campana F; Macé S; Chiron M; van de Velde H; Mikhael J
    Blood Cancer J; 2021 Mar; 11(3):55. PubMed ID: 33712562
    [No Abstract]   [Full Text] [Related]  

  • 4. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
    Richardson PG; Harrison SJ; Bringhen S; Schjesvold F; Yong K; Campana F; Le-Guennec S; Macé S; Dimopoulos MA
    Future Oncol; 2021 Dec; 17(34):4797-4812. PubMed ID: 34521277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
    Martin T; Richardson PG; Facon T; Moreau P; Perrot A; Spicka I; Bisht K; Inchauspé M; Casca F; Macé S; Van de Velde H; Suzuki K
    Haematologica; 2022 Oct; 107(10):2485-2491. PubMed ID: 35734925
    [No Abstract]   [Full Text] [Related]  

  • 9. Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis.
    Sunami K; Ikeda T; Huang SY; Wang MC; Koh Y; Min CK; Yeh SP; Matsumoto M; Uchiyama M; Iyama S; Shimazaki C; Lee JH; Kim K; Kaneko H; Kim JS; Lin TL; Campana F; Tada K; Iida S; Suzuki K;
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e751-e761. PubMed ID: 35641409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
    Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
    Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
    [No Abstract]   [Full Text] [Related]  

  • 11. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.
    Schjesvold F; Richardson PG; Facon T; Alegre A; Spencer A; Jurczyszyn A; Sunami K; Frenzel L; Min CK; Guillonneau S; Lin PL; Le-Guennec S; Campana F; Van de Velde H; Bensfia S; Bringhen S
    Haematologica; 2022 Mar; 107(3):774-775. PubMed ID: 35229573
    [No Abstract]   [Full Text] [Related]  

  • 12. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
    Dimopoulos MA; Leleu X; Moreau P; Richardson PG; Liberati AM; Harrison SJ; Miles Prince H; Ocio EM; Assadourian S; Campana F; Malinge L; Sémiond D; van de Velde H; Yong K
    Leukemia; 2021 Feb; 35(2):562-572. PubMed ID: 32444867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isatuximab: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(9):905-912. PubMed ID: 32347476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
    Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
    Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
    Rachedi F; Koiwai K; Gaudel-Dedieu N; Sebastien B; Thai HT; Brillac C; Fau JB; Nguyen L; van de Velde H; Veyrat-Follet C; Semiond D
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):766-777. PubMed ID: 35355430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.